首页> 外文OA文献 >PDB91 Comparative Persistency with Newer agents used to Treat Type 2 Diabetes (T2dm) In the united states: canagliflozin Versus Dipeptidyl Peptidase-4 (Dpp-4) Inhibitors and Glucagon-Like Peptide-1 (Glp-1) agonists

【2h】

PDB91 Comparative Persistency with Newer agents used to Treat Type 2 Diabetes (T2dm) In the united states: canagliflozin Versus Dipeptidyl Peptidase-4 (Dpp-4) Inhibitors and Glucagon-Like Peptide-1 (Glp-1) agonists

机译：PDB91与用于治疗2型糖尿病（T2dm）的新型药物的比较持久性在美国：canagliflozin与Depteptidyl Peptidase-4（Dpp-4）抑制剂和胰高血糖素样肽1（Glp-1）激动剂。

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Diels J.; Neslusan C.;
展开▼
作者单位

展开▼
年度 2015
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Cost Effectiveness of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists, and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: A Systematic Review [J] . Hong Dongzhe, Si Lei, Jiang Minghuan, PharmacoEconomics . 2019,第6期

机译：钠葡萄糖COTRANSPORPOR-2（SGLT2）抑制剂，胰高血糖素样肽-1（GLP-1）受体激动剂和二肽基肽酶-4（DPP-4）抑制剂的成本有效性：系统审查
2. Cost Effectiveness of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists, and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: A Systematic Review (vol 37, pg 777, 2019) [J] . Hong Dongzhe, Si Lei, Jiang Minghuan, PharmacoEconomics . 2019,第12期

机译：钠 - 葡萄糖Cotroansporter-2（SGLT2）抑制剂，胰高血糖素样肽-1（GLP-1）受体激动剂和二肽基肽酶-4（DPP-4）抑制剂的成本有效性：系统评价（Vol 37，PG 777， 2019）
3. Dipeptidyl peptidase-4 (DPP-4) inhibitors are favourable to Glucagon-Like Peptide-1 (GLP-1) agonists: No [J] . MadsbadS. European journal of internal medicine . 2012,第2期

机译：二肽基肽酶4（DPP-4）抑制剂对胰高血糖素样肽1（GLP-1）激动剂有利：否
4. Fragment-Based Drug Design to Discover Novel Inhibitor of Dipeptidyl Peptidase-4 (DPP-4) as a Potential Drug for Type 2 Diabetes Therapy [C] . Eka Gunarti Ningsih, Muhammad Fauzi Hidayat, Usman Sumo Friend Tambunan International work-conference on bioinformatics and biomedical engineering . 2019

机译：基于片段的药物设计，发现二肽基肽酶-4（DPP-4）的新型抑制剂作为2型糖尿病治疗的潜在药物
5. Comparative Effectiveness of Dipeptidyl Peptidase-4 (DPP-4) Inhibitors and Human Glucagon-Like Peptide-1 (GLP-1) Analogue as Add-On Therapies to Sulphonylurea among Diabetes Patients in the Asia-Pacific Region: A Systematic Review [O] . Martin C. S. Wong, Harry H. X. Wang, Mandy W. M. Kwan, -1

机译：二肽基肽酶-4（DPP-4）抑制剂和人胰高血糖素样肽-1（GLP-1）类似物作为磺脲类药物在亚太地区糖尿病患者中的附加疗法的比较有效性：系统评价
6. Comparative effectiveness of dipeptidyl peptidase-4 (DPP-4) inhibitors and human glucagon-like peptide-1 (GLP-1) analogue as add-on therapies to sulphonylurea among diabetes patients in the Asia-Pacific region: a systematic review. [O] . Martin C S Wong, Harry H X Wang, Mandy W M Kwan, 2014

机译：二肽基肽酶-4（Dpp-4）抑制剂和人胰高血糖素样肽-1（GLp-1）类似物作为亚太地区糖尿病患者磺脲类药物的附加疗法的比较效果：系统评价。

PDB91 Comparative Persistency with Newer agents used to Treat Type 2 Diabetes (T2dm) In the united states: canagliflozin Versus Dipeptidyl Peptidase-4 (Dpp-4) Inhibitors and Glucagon-Like Peptide-1 (Glp-1) agonists

著录项

引文网络

相似文献

相关主题

期刊订阅